Serial Liver Stiffness Measurement and Fibrosis-4 Scores in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Dynamics
Fibroscan
Non-invasive test
VCTE
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
received:
02
07
2024
accepted:
05
10
2024
medline:
16
10
2024
pubmed:
16
10
2024
entrez:
15
10
2024
Statut:
aheadofprint
Résumé
In patients with metabolic dysfunction-associated steatotic liver disease (MASLD), there are limited data on how changes in FIB4 and liver stiffness measurement (LSM) correlate in non-biopsy cohorts. Our objective was to evaluate associations between changes in FIB4 and LSM in MASLD patients. We included MASLD patients with serial VCTE from 2015-2022. The primary predictors were change in FIB4 and presence of diabetes, obesity, and high alanine aminotransferase (ALT). The primary outcome, applied only to patients with LSM1 < 8 kPa, was incident significant fibrosis (SF) defined as a ≥ 20% increase in LSM2 vs. LSM1 and LSM2 ≥ 8 kPa. A secondary outcome was LSM progression with a similar definition but applied to all participants, not only those with LSM1 < 8 kPa. Of 285 included patients, 216 had LSM1 < 8 kPa and were included in the primary analysis; of these, 34 (16%) had incident SF. Changes in FIB4 correlated with changes in LSM (R = 0.16, p = 0.016). Independent predictors of incident SF included comorbid diabetes mellitus (OR 2.43, 95% CI 1.04-6.56), obesity (OR 3.88, 95% CI 1.63-9.25), and baseline ALT ≥ 30 (OR 8.55, 95% CI 1.10-66.29). A model including ALT, diabetes, and obesity outperformed a model with FIB4 change alone. Among patients with MASLD, changes in FIB4 correlated with changes in LSM but more significant correlates of incident significant fibrosis included diabetes mellitus, obesity, and high baseline ALT.
Sections du résumé
BACKGROUND
BACKGROUND
In patients with metabolic dysfunction-associated steatotic liver disease (MASLD), there are limited data on how changes in FIB4 and liver stiffness measurement (LSM) correlate in non-biopsy cohorts.
AIMS
OBJECTIVE
Our objective was to evaluate associations between changes in FIB4 and LSM in MASLD patients.
METHODS
METHODS
We included MASLD patients with serial VCTE from 2015-2022. The primary predictors were change in FIB4 and presence of diabetes, obesity, and high alanine aminotransferase (ALT). The primary outcome, applied only to patients with LSM1 < 8 kPa, was incident significant fibrosis (SF) defined as a ≥ 20% increase in LSM2 vs. LSM1 and LSM2 ≥ 8 kPa. A secondary outcome was LSM progression with a similar definition but applied to all participants, not only those with LSM1 < 8 kPa.
RESULTS
RESULTS
Of 285 included patients, 216 had LSM1 < 8 kPa and were included in the primary analysis; of these, 34 (16%) had incident SF. Changes in FIB4 correlated with changes in LSM (R = 0.16, p = 0.016). Independent predictors of incident SF included comorbid diabetes mellitus (OR 2.43, 95% CI 1.04-6.56), obesity (OR 3.88, 95% CI 1.63-9.25), and baseline ALT ≥ 30 (OR 8.55, 95% CI 1.10-66.29). A model including ALT, diabetes, and obesity outperformed a model with FIB4 change alone.
CONCLUSION
CONCLUSIONS
Among patients with MASLD, changes in FIB4 correlated with changes in LSM but more significant correlates of incident significant fibrosis included diabetes mellitus, obesity, and high baseline ALT.
Identifiants
pubmed: 39407080
doi: 10.1007/s10620-024-08683-4
pii: 10.1007/s10620-024-08683-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Le MH, Yeo YH, Li X et al. Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019;2022:2809–2817.
Kim D, Cholankeril G, Loomba R, Ahmed A. Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017–2018. J Gen Intern Med. 2021. https://doi.org/10.1007/s11606-021-06677-w .
doi: 10.1007/s11606-021-06677-w
pubmed: 34704207
pmcid: 9360271
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–1835.
doi: 10.1097/HEP.0000000000000323
pubmed: 36727674
Ng CH, Lim WH, Hui Lim GE et al. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21:e935.
doi: 10.1016/j.cgh.2022.04.014
Ekstedt M, Hagstrom H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–1554.
doi: 10.1002/hep.27368
pubmed: 25125077
Hagstrom H, Nasr P, Ekstedt M et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265–1273.
doi: 10.1016/j.jhep.2017.07.027
pubmed: 28803953
Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology. 2018;155:e417.
doi: 10.1053/j.gastro.2018.04.034
Sanyal AJ, Van Natta ML, Clark J et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021;385:1559–1569.
doi: 10.1056/NEJMoa2029349
pubmed: 34670043
pmcid: 8881985
Kanwal F, Shubrook JH, Adams LA et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021;161:1657–1669.
doi: 10.1053/j.gastro.2021.07.049
pubmed: 34602251
European Association for the Study of the Liver . Electronic address eee, European Association for the Study of D, European Association for the Study of O, European Association for the Study of the L. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) J Hepatol. 2024.
McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148–1155.
doi: 10.1016/j.jhep.2014.11.034
pubmed: 25477264
Huang DQ, Wilson LA, Behling C et al. Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study. Gastroenterology. 2023;165:e465.
doi: 10.1053/j.gastro.2023.04.025
Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285.
doi: 10.1111/j.1365-2036.2011.04724.x
pubmed: 21623852
Canbay A, Kachru N, Haas JS, Sowa J-P, Meise D, Ozbay AB. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 2020;52:1185–1194.
doi: 10.1111/apt.16016
Daijo K, Nakahara T, Inagaki Y et al. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. J Gastroenterol Hepatol. 2020;35:1412–1419.
doi: 10.1111/jgh.14968
pubmed: 31896166
Lin H, Lee HW, Yip TC et al. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease. JAMA. 2024. https://doi.org/10.1001/jama.2024.1447 .
doi: 10.1001/jama.2024.1447
pubmed: 39374319
pmcid: 10985619
Loomba R, Huang DQ, Sanyal AJ et al. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut. 2022. https://doi.org/10.1136/gutjnl-2022-327777 .
doi: 10.1136/gutjnl-2022-327777
pubmed: 36750244
Braude M, Roberts S, Majeed A et al. Liver stiffness (Fibroscan(R)) is a predictor of all-cause mortality in people with non-alcoholic fatty liver disease. Liver Int. 2022. https://doi.org/10.1111/liv.15415 .
doi: 10.1111/liv.15415
pubmed: 36050821
pmcid: 10086842
Hagstrom H, Talback M, Andreasson A, Walldius G, Hammar N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol. 2020;73:1023–1029.
doi: 10.1016/j.jhep.2020.06.007
pubmed: 32621944
Lee J, Vali Y, Boursier J et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int. 2021;41:261–270.
doi: 10.1111/liv.14669
pubmed: 32946642
pmcid: 7898346
Seo YG, Polyzos SA, Park KH, Mantzoros CS. Fibrosis-4 Index Predicts Long-Term All-Cause, Cardiovascular and Liver-Related Mortality in the Adult Korean Population. Clin Gastroenterol Hepatol. 2023;21:3322–3335.
doi: 10.1016/j.cgh.2023.04.026
pubmed: 37164111
Wong YJ, Urias E, Song MW et al. Combination of Fibrosis-4, liver-stiffness measurement, and Fibroscan-AST score to predict liver-related outcomes in nonalcoholic fatty liver disease. Hepatology Communications. 2023. https://doi.org/10.1097/HC9.0000000000000244 .
doi: 10.1097/HC9.0000000000000244
pubmed: 38055646
pmcid: 10984662
Chalasani N, Abdelmalek MF, Loomba R et al. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int. 2019;39:924–932.
doi: 10.1111/liv.13974
pubmed: 30253043
pmcid: 6433535
Barritt AS, Watkins S, Gitlin N et al. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. Hepatology Communications. 2021. https://doi.org/10.1002/hep4.1689 .
doi: 10.1002/hep4.1689
pubmed: 34708575
pmcid: 8652790
Semmler G, Yang Z, Fritz L et al. Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease. Gastroenterology. 2023. https://doi.org/10.1053/j.gastro.2023.06.030 .
doi: 10.1053/j.gastro.2023.06.030
pubmed: 37442301
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76:959–974.
doi: 10.1016/j.jhep.2021.12.022
pubmed: 35120736
Wong YJ, Chen VL, Abdulhamid A et al. Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients. Hepatology. 2024. https://doi.org/10.1097/HEP.0000000000000891 .
doi: 10.1097/HEP.0000000000000891
pubmed: 39255517
Jasty VSJ, Urias E, Le Ashley Tiong K et al. Prognostic Accuracy of Transient Elastography-Based Predictors in Diabetes and Obesity: A Multicenter International Cohort Study. Digestive Diseases and Sciences. 2024. https://doi.org/10.1007/s10620-024-08635-y .
doi: 10.1007/s10620-024-08635-y
pubmed: 39322805
Suresh D, Li A, Miller MJ, Wijarnpreecha K, Chen VL. Associations between metabolic hyperferritinaemia, fibrosis-promoting alleles and clinical outcomes in steatotic liver disease. Liver International. 2023. https://doi.org/10.1111/liv.15787 .
doi: 10.1111/liv.15787
pubmed: 37971775
Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–1986.
pubmed: 37363821
Wong YJ, Zhaojin C, Tosetti G et al. Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients. Clin Mol Hepatol. 2023;29:135–145.
doi: 10.3350/cmh.2022.0181
pubmed: 36064306
Thorhauge KH, Semmler G, Johansen S et al. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease. J Hepatol. 2024;81:23–32.
doi: 10.1016/j.jhep.2024.02.019
pubmed: 38428644
Tan EX, Huang DQ, Yee NTS et al. Upper limit of normal ALT levels in health and metabolic diseases: Pooled analysis of 423,355 individuals with bootstrap modelling. Aliment Pharmacol Ther. 2024;59:984–992.
doi: 10.1111/apt.17914
pubmed: 38372477
Chen VL, Oliveri A, Miller MJ et al. PNPLA3 genotype and diabetes identify patients with non-alcoholic fatty liver disease at high risk of incident cirrhosis. Gastroenterology. 2023;164:966–977.
doi: 10.1053/j.gastro.2023.01.040
pubmed: 36758837
Siddiqui MS, Yamada G, Vuppalanchi R et al. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. Clin Gastroenterol Hepatol. 2019;17:e1875.
doi: 10.1016/j.cgh.2018.12.031
Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66:1486–1501.
doi: 10.1002/hep.29302
pubmed: 28586172